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Prostate cancer (PC) is the second leading cause of cancer death in men. Recent reports suggest that excess of nutrients involved in
the one-carbon metabolism pathway increases PC risk; however, empirical data are lacking. Veteran American men (272 controls
and 144 PC cases) who attended the Durham Veteran American Medical Center between 2004–2009 were enrolled into a case-
control study. Intake of folate, vitamin B12, B6, and methionine were measured using a food frequency questionnaire. Regression
models were used to evaluate the association among one-carbon cycle nutrients, MTHFR genetic variants, and prostate cancer.
Higher dietary methionine intake was associated with PC risk (OR = 2.1; 95%CI 1.1–3.9) The risk was most pronounced in men
with Gleason sum <7( O R= 2.75; 95%CI 1.32– 5.73). The association of higher methionine intake and PC risk was only apparent
in men who carried at least one MTHFR A1298C allele (OR = 6.7; 95%CI = 1.6–27.8), compared to MTHFR A1298A noncarrier
men (OR = 0.9; 95%CI = 0.24–3.92) (p-interaction = 0.045). There was no evidence for associations between B vitamins (folate,
B12, and B6) and PC risk. Our results suggest that carrying the MTHFR A1298C variants modiﬁes the association between high
methionine intake and PC risk. Larger studies are required to validate these ﬁndings.
1.Introduction
Prostate cancer (PC) is the most commonly diagnosed ma-
lignancy in men, and the second leading cause of cancer
death in men globally [1]. Age adjusted PC incidence
and mortality exhibits considerable geographic and racial
variation, suggesting that both heritable and environmen-
tally acquired/dietary factors are important [2, 3]. Regarding
dietary factors, either deﬁciencies or excesses of nutrients
involved in the one-carbon metabolism pathway have been
hypothesized to increase PC risk, but ﬁndings are incon-
sistent [4–15]. The one-carbon cycle is necessary for both2 Journal of Cancer Epidemiology
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Figure 1: A simpliﬁed representation of the one-carbon metabolism pathway.
cellular proliferation and epigenetic modiﬁcation and folate
is a critical component of this pathway. Folate functions
as an important source of carbon moieties in the synthe-
sis of nucleotides that are essential for DNA repair and
replication. The important role of folate is illustrated by
the mutations and chromosomal damage associated with
its deﬁciency. These eﬀects are central to the eﬃcacy of
antifolate chemotherapeutic agents (e.g., methotrexate) as
tumor therapeutics. Folate is also essential in the conversion
of methionine to its derivative, S-adenosylmethionine, the
principal methyl donor [16], which transfers methyl groups
to molecules key for several processes, including DNA
synthesis and repair [17]. The predominant form of folate
in circulation is 5-methylenehydrofolate (5-methyl THF),
which becomes available when methylenetetrahydrofolate
reductase (MTHFR) converts 5,10-methyl THF to 5-methyl
THF [18]. This latter form of folate (5-methyl THF) is essen-
tial in the remethylation of homocysteine to methionine,
a reaction catalyzed by vitamin B12 (Figure 1). Further-
more, 5,10-methylenehydrofolate promotes the synthesis of
thymidylate from uracil minimizing the misincorporation of
uracil into DNA, which could play a protective role in cancer
development [19].
Numerous tumor tissues, including PC, show a general
pattern of global DNA hypomethylation and gene-speciﬁc
hypermethylation [20], suggesting one carbon-cycle deﬁ-
ciency or excess may play a role in tumor development or
progression.Lowfolatelevels,whethermeasuredintheusual
diet [21–23] or in circulation [24], have been previously
associated with higher risk of breast, lung, pancreatic, and
colorectal cancer, and high folate levels have been associated
with lower risk of some [23], but not all cancers [8,
25, 26]. However, more recent studies [7]h a v er e p o r t e d
elevated PC risk in relation to high plasma folate levels,
while dietary folate [4] was associated with lower PC risk;
yet others [6, 9] found no association between circulating
concentrations of folate and PC risk in Europe and in USA.
These inconsistencies in ﬁndings may be due to genetic
or nutritional diﬀerences inherent in the two populations
[23, 27, 28]. Some [29, 30] have hypothesized that part of the
increase in incidence in many adenocarcinomas overthe past
several years is, in part, due to excessive folate resulting from
fortiﬁcation of milled grain in Western countries, which in
USA. and Canada occurred in 1998 [31]. These inconsistent
ﬁndingscouldalsobeduetoassessmentofsinglenutrientsin
this pathway, not taking into account their synergistic func-
tional interaction with other nutrients. Disentangling these
relationships will improve our understanding of potential
mechanisms underlying these methyl group donor nutrients
and PC, ultimately guiding prevention eﬀorts. Herein, we
evaluated whether upper intake levels of key nutrients in the
one-carbon cycle: folate, vitamins B12, B6, and methionine,
areassociatedwithincreasedPCriskamongBlackandWhite
American veterans. To glean mechanistic insights into these
associations,wefurtherexaminedtheextenttowhichgenetic
variants of the MTHFR gene [32] modify the association
between nutrient intake and PC risk.
2.MaterialandMethods
2.1. Study Design and Participants. Data collection methods
have been described elsewhere [33, 34]. Men who had been
screened for PC with a serum PSA in the last 12 months were
recruited to participate in an ongoing case-control study at
the Durham Veterans Aﬀairs Medical Center (DVAMC) in
Durham, NC, from January 2007 to November 2009. AllJournal of Cancer Epidemiology 3
subjects were at least 18 years old and had no history of
prostatecancer.Caseswerenewpatientswithbiopsy-positive
prostate cancer who were scheduled for a prostate needle
biopsy at the urology clinic at the DVAMC, due to elevated
PSAand/orabnormalrectalexamination.Ofthe485patients
scheduled for a biopsy, 420 had the biopsy done and 166
of these had biopsy-positive prostate cancer. Analyses for
the present study were restricted to patients who completed
the dietary questionnaire (N = 144), a participation rate of
86.7% (144/166). Controls were patients identiﬁed through
the outpatient urology and primary care clinics at the
DVAMC (the same center from which cases were recruited)
and had not been recommended for a prostate needle
biopsy. Conditions for which these patients were seen were
not associated with intake of folate or other one-carbon
nutrients. These nonhospitalized patients referred to these
clinics were eligible for enrollment regardless of the reason
for referral. Controls also had to have no history of PC and
had a PSA test within one year of enrollment into the study.
Controls were not diagnosed with diseases associated with
intake of folate nor other one-carbon nutrients. Of the 421
eligible controls, 272 completed the dietary questionnaire,
yielding a 64.5% (272/421) participation rate. This study was
approved by the Duke University and DVAMC Institutional
ReviewBoardsandallpatientssignedawrittenconsentform.
2.2. Data Collection. Trained interviewers collected ques-
tionnaire data, obtained anthropometric measurements
(weight and height), and abstracted medical records. Weight
was measured using a digital scale, and a stadiometer was
used to measure height [35]. These measurements were used
to calculate body mass index (BMI), deﬁned as weight (in
kilograms) divided by the square of height (in meters
squared).Allquestionnaireswereself-administeredandtypi-
callyﬁlledoutthedayofthescheduledclinicvisitorreturned
shortly thereafter by mail prior to the patient knowing the
outcome of their biopsy. Risk factor questionnaires queried
information on sociodemographic characteristics, lifestyle
factorssuchassmokingandalcoholuse,medicationuse,and
family history of PC.
Dietary information was obtained using the Harvard
food frequency questionnaire (FFQ), developed and tested
by [36]. This 61-item food frequency questionnaire assessed
the frequency of consumption according to prespeciﬁed por-
tion sizes for each food and beverage item. Subjects reported
their intake in the past 12 months, and this time period
was selected to account for seasonal variation in consump-
tion. Daily food, nutrient, and total energy intakes were
determined using the reported frequency of consumption
and portion sizes. The nutrients of interest for this study
were one carbon cycle nutrients measurable in FFQs: folate,
vitamin B6, vitamin B12, and methionine. Nutrient intake
for each food item was computed by multiplying the relative
frequency of consumption by the nutrient content of the
prespeciﬁed portion size using USDA food composition
sources [37] and data from manufacturers [38, 39]. Nutrient
intake also incorporated reported supplementation. Folic
acid is added to fortiﬁed foods in USA, and natural foods
containing these vitamins were also measured and included
in the estimates.
2.3. DNA Sample Preparation and Genotyping. DNA was iso-
latedfromperipheralbloodbystandardDNAisolation(Qia-
gen Inc., Valencia, CA, USA) and quantiﬁed by ultraviolet
spectrophotometry.Priortogenotyping,DNAconcentration
was determined using PicoGreen assay (Life Technologies,
Gaithersburg, MD) and measured using the ﬂuorescence
intensity measurements plotted against a standard curve
that was generated from the average ﬂuorescence intensity
of standards run in replicate. Based on the PicoGreen
quantiﬁcation, 10ng of genomic DNA from each sample
was used in the iPlex assay for Sequenom-iPlex Genotyping
(Sequenom Inc, San Diego, CA).
The Sequenom MassArray Platform (Sequenom Inc, San
Diego, CA) was used to assay for MTHRF variants rs1801133
andrs1801131. Sequenomonlineassaytools(AssayDesigner
4.0) were used to design the iPlex assay for the variants
as part of a multiplex reaction to query 16 diﬀerent SNPs.
The data were analyzed by Sequenom-Typer 4.0 software.
The Sequenom-iPlex genotyping and analysis was validated
with CEPH gDNA controls by performing the iPlex assay
and scanning on the MALDI-TOF Mass Spectrometer. The
genotyping and analysis was performed at the David H.
MurdockResearchInstitute(DHMRI)GenomicsLaboratory
(Kannapolis, NC). At the time of this analysis, 364 samples
were submitted and 358 successfully produced good spectra
for genotyping at a failure rate of <2.2%. The Post-QC (Call
Rate) of MTHRF variants rs1801133 and rs1801131 was
99.70%.
2.4. Statistical Analyses. Our hypothesis was to examine
whether higher than recommended intake of one carbon
nutrients was associated with PC risk and whether this
association was similar in low-grade versus high-grade PC.
Low-grade PC was deﬁned as Gleason sum <7 and high-
grade was deﬁned as Gleason ≥7. Nutrient intake derived
from FFQs was estimated for 4 one carbon cycle nutrients,
and then dichotomized as either high if the nutrient
intake was at above the recommended upper limit, or low,
which included normal and below the recommended levels.
Cut-oﬀs for folate, vitamins B-6, B-12, and methionine
were made at higher than recommended dietary allowance
(RDA) by the Food and Nutrition Board (FNB) and the
Institute of Medicine (IOM). High folate was >700 mcg/day
(recommended is 400mcg/day), high vitamin B12 was
>25mcg/day (recommended is 2.4mcg/day), high vitamin
B6 was >4.5mg/day (recommended is 1.7mg/day), and high
methionine was >2.6g/day (based on a US standard diet
of 50–100g protein/day, which would render 1.5–3.0g/day
of methionine, Dr. Scornik at Dartmouth College, personal
communication).
Potential confounders (age, height, and BMI) were
normally distributed overall and were treated as contin-
uous variables in modeling. Race was self-reported and
categorized as African American, White, and other (Native
AmericanandLatino).Familyhistoryincludedwasmaternal4 Journal of Cancer Epidemiology
Table 1: Risk factor characteristics for prostate cancer participants.
Risk factor
Cases n = 144
n (%)
Mean (SD)
Controls n = 272
n (%)
Mean (SD)
Age 63.12 (5.62) 61.77 (7.46) P = 0.06
Height (in.) 69.63 (2.68) 69.83 (2.89) P = 0.51
Obesity (BMI) 29.39 (5.51) 30.74 (5.64) P = 0.02
Race P = 0.0002
African American 78 (54.55) 92 (33.95)
Caucasian 64 (44.76) 174 (64.21)
Other 1 (0.70) 5 (1.85)
Family history PC P = 0.0072
Yes 34 (23.61) 36 (13.24)
No 110 (76.39) 236 (86.76)
Drinking status P = 0.5547
Current drinker 62 (43.06) 109 (40.07)
Former drinker 80 (55.56) 155 (56.99)
Never drinker 2 (1.39) 8 (2.94)
Tobacco use P = 0.0017
Current smoker 47 (32.64) 61 (22.43)
Former smoker 96 (66.67) 200 (73.53)
Never smoker 1 (0.69) 11 (4.04)
Gleason < 7
(44 Black/33 White) 76 (53.15) NA
Score ≥ 7
(37 Black/31White) 67 (46.85)
lineage (maternal uncle) or paternal lineage (father, brother,
or paternal uncle) (yes or no) and these combined. Data
on drinking and smoking were also self-reported and
categorized into current, former, and never categories.
Descriptive statistics (means, SD) and percentages for
cases and controls were used to compare using X2 tests
for categorical variables and Wilcoxon rank sum test for
continuous variables. Means and standard deviations for B-
vitamins and methionine were compared between PC cases
andcontrolsandbetweenMTHFRgenotypes.Unconditional
logistic regression was used to estimate the odd ratios
(ORs) and 95% conﬁdence intervals (95%CI)—for the
association between high nutrient intake, genotypes, and
PC risk. Multinomial analyses were used for low-grade and
high-grade PC, using no-cancer as reference. Confounders
adjusted for in all models were age, race, family history
of PC, BMI, and smoking and drinking status, which are
confounders in the population and in this population. All
analysesweredone using SAS version9.2(SASInstitute,Inc.,
Cary, NC).
3. Results
The clinical characteristics of the study participants are
described in Table 1.P Cc a s e s( n = 144) and controls (n =
272) were comparable in age (P = 0.06) and height (P =
0.51). Controls (mean BMI = 30.74, SD = 5.64), however,
had higher BMI than cases (mean BMI = 29.39, SD = 5.51,
P = 0.02). African Americans comprised 55% of the cases
but only 34% of the controls (P = 0.0002). A family history
of PC was present for 24% of the cases, versus 13% in the
controls (P = 0.0072). Both cases and controls were either
current or former smokers (P = 0.002). Low-grade disease
was found in 53% of cases.
Table 2 shows the associations between folate, vitamins
B6, B12, and methionine intake in controls and PC cases,
the latter further stratiﬁed into high grade (Gleason ≥ 7)
and low grade (Gleason < 7). Compared to men reporting
lower intake ≤700mcg/day, those reporting higher folate
intake had similar overall PC risk (OR = 1.02, 95%CI 0.63–
1.64) after adjusting for potential confounders. Although
neither risk estimate reached statistical signiﬁcance, when
cases were stratiﬁed into low and high grade, there was an
inverseassociationbetweenhighfolateintakeandhigh-grade
PC (OR = 0.68, 95%CI 0.35–1.34) and a positive association
with low-grade disease (OR = 1.42, 95%CI = 0.81–2.47).
Similar patterns of association were observed when vitamin
B6 intake was evaluated. In contrast, high vitamin B12
intake associations with both HG PC and LG PC were
not statistically signiﬁcant. The only signiﬁcant observation
was that high intake of methionine was associated with
increased PC risk (OR = 2.1, 95%CI 1.1–3.9, P = 0.02),
whencomparedtointake≤2.6g/day.Theseassociationswere
somewhat stronger for low-grade PC (OR = 2.8, 95%CI 1.3–
5.7, P = 0.007). While of lower magnitude than for low-
grade disease, these associations were in a similar direction
for high-grade disease (OR = 1.44, 95%CI 0.58–3.54, P =
0.43). These patterns of association were similar in African
Americans and Whites (data not shown).
WeexploredwhetherPCriskvariedbycommonMTHFR
polymorphisms (Table 3). The frequency of these genotypes
in controls were similar to those in HapMap where minor
allele frequency (TT) was 8% and CT frequency was 31%
for 677CT, and minor allele frequency (CC) was 7% and
AC frequency was 37% for the 1298 SNP. In PC cases, 66%
were homozygous for the MTHFR C677T wild-type allele
“CC”, versus 35% that carried either 677CT (24%) or 677TT
(11%). In controls, 54% were homozygous for the C677T
wild-type allele (CC), and 46% were either homozygous
(TT: 37%) or heterozygous (CT: 9%) carriers of the MTHFR
variant; these variants were in HWE (P = 0.27). Sixty-
six percent of PC cases were wild type for the A1298C
variant, and 35% carried the heterozygous (1298AC: 31%)
or homozygous (1298CC: 4%) variant. Fifty-three percent
of the controls were homozygous for the A1298C wild-type
allele (AA), and 47% were either homozygous (CC: 6%) or
heterozygous (CA: 41%) carriers of the MTHFR variant, and
they did not deviate from HWE (P = 0.41). We observed no
signiﬁcant association between carrying the MTHFR C677T
(OR = 0.7, 95%CI 0.3–1.3) or MTHFR A1298C (OR = 0.70,
95%CI 0.37–1.33, P = 0.28) and PC risk (Table 3).
To further evaluate the interaction of high methionine
intake and PC risk association by MTHFR genotypes, we
measure OR and 95%CI in PC cases. The association
between higher methionine intake and PC risk did not vary
signiﬁcantlybyMTHFRC677Tgenotype(Table4).However,
we observed considerable variation between methionineJournal of Cancer Epidemiology 5
Table 2: Folate, vitamins B6, B12, and methionine intake∗ in total PC, HG, and LG cases and controls.
Nutrient Controls
n = 272
Total PC
n = 144
OR∗∗ (95%CI), P value
HG PC
n = 68
OR∗∗ (95%CI), P value
LG PC
n = 77
OR∗∗ (95%CI), P value
Folate
Low/normal (≤700mcg/day) 188 102 54 49
High (>700mcg/day) 84 42 14 28
1.02 (95%CI; 0.64–1.63) 0.68 (95%CI; 0.35–1.34) 1.42 (95%CI; 0.81–2.47)
P = 0.95 P = 0.26 P = 0.21
B6
Low/normal (≤4.5mg/day) 206 113 57 57
High (>4.5mg/day) 66 31 11 20
0.92 (95%CI; 0.55–1.54) 0.65 (95%CI; 0.31–1.33) 1.24 (95%CI; 0.67–2.7)
P = 0.76 P = 0.22 P = 0.48
B12
Low/normal (≤25mcg/day) 209 107 52 56
High (>25mcg/day) 63 37 16 21
1.29 (95%CI; 0.78–2.12) 1.12 (95%CI; 0.56–2.16) 1.38 (95%CI; 0.74–2.5)
P = 0.32 P = 0.77 P = 0.31
Methionine
Low/normal (≤2.6g/day) 249 119 60 60
High (>2 . 6 g / d a y ) 2 3 2 581 7
2.08 (95%CI; 1.10–3.90) 1.44 (95%CI; 0.58–3.54) 2.75 (95%CI; 1.32–5.73)
P = 0.02 P = 0.43 P = 0.007
∗Adjusted for age, race, family history of PC, BMI, and smoking status.
∗∗Referents are subjects in the low intake group of each nutrient of interest.
PC: prostate cancer.
HG PC: high grade (Gleason ≥ 7).
LG PC: low grade (Gleason < 7).
Table 3: ORs and 95%CI for the association between MTHFR gene polymorphisms∗ and PC risk.
PC cases n = 55 Controls n = 192 OR (95%CI), P value
Frequency (%) Frequency (%)
MTHFR polymorphism C677T
CC (homo wild type) 36 (65.45) 103 (53.65) 1.0
CT (hetero) and TT (homo) 19 (34.55) 89 (46.35) 0.67 (0.34–1.31), P = 0.23
MTHFR polymorphism A1298C
AA (homo wild type) 36 (65.45) 103 (53.37) 1.0
AC (hetero) and CC (homo) 19 (34.55) 90 (46.63) 0.70 (0.37–1.33), P = 0.28
∗Adjusted for age, race, BMI, and smoking status.
intake and PC risk in carriers of MTHFR A1298C (OR =
6.7, 95%CI 1.6–27.8) compared to noncarriers (OR = 1.0,
95%CI = 0.2–3.9). The cross-product term for MTHFR
A1298C and methionine was statistically signiﬁcant (P =
0.045). Thus, high methionine intake association with PC
risk seems to be linked to the MTHFR A1298C polymor-
phism in this population.
4. Discussion
Our key ﬁndings were that high intake of methionine, which
after its conversion to S-adenosylmethionine becomes the
principal methyl donor for DNA methylation, was associated
with higher overall risk of PC and that association was only
evident in men with carriers of the MTHFR A1298C geno-
type. These associations remained essentially unchanged
when analyses were restricted to African Americans or
Whites. Associations between B vitamins and PC risk were
unremarkableandinconsistentandnotmodiﬁedbyMTHFR
genotypes. Our ﬁndings are consistent with the hypothesis
that excessive intake of a key one-carbon cycle nutrient may
be associated with PC risk, particularly in carriers of the
MTHFRA1298Cgenotype.ThisincreasedPCriskispossibly
due to acceleration of growth of preexisting neoplasms [40],
though these results require validation in other and larger
datasets.6 Journal of Cancer Epidemiology
Table 4: ORs and 95%CI for the association between methionine intake and PC risk in carriers and noncarriers of C677T and A1298C
MTHFR gene polymorphisms∗.
PC cases n = 55
Frequency (%)
Controls n = 192
Frequency (%) OR (95%CI), P value
Methionine > 2.6g/day in
MTHFR polymorphism C677T carriers
CC (homo wild type) 36 (65.45) 103 (53.65) OR = 1.96 (0.59–6.41), P = 0.26
CT (hetero) and TT (homo) 19 (34.55) 89 (46.35) OR = 2.93 (0.7–12.24), P = 0.14
Methionine > 2.6g/day in
MTHFR polymorphism A1298C carriers
AA (homo wild type) 36 (65.45) 103 (53.37) OR = 0.97 (0.24–3.92), P = 0.97
AC (hetero) and CC (homo) 19 (34.55) 90 (46.63) OR = 6.67 (1.59–27.83), P = 0.01
∗Adjusted for age, race, BMI, and smoking status.
Mechanisms by which higher methionine intake could
increase PC risk remain speculative. Although these results
could have been due to chance alone, methionine is the
key player in the one-carbon metabolism cycle as after
conversion to S-adenosylmethionine it becomes the prin-
cipal methyl donor for DNA methylation, an epigenetic
phenomenon associated with cancer [41]. Our ﬁndings that
high methionine intakes were associated with increased
PC risk, may imply that methionine availability at higher
than optimal levels may lead to higher bioavailability of
S-adenosylmethionine to donate methyl groups to DNA,
resulting in DNA hypermethylation of regulatory regions
of key genes, including tumor suppressors. For exam-
ple, hypermethylation of the CpG promoter sequences of
tumor suppressor genes and the GSTP-P1 (glutathione-S-
transferase) gene is the most frequent alteration in PC cells
and may be associated with prostatic tumorigenesis [42].
Alternatively, higher bioavailable methionine levels could
also disrupt the physiologic equilibrium concentrations of
S-adenosylmethionine and homocysteine, reducing MTHFR
activity [43, 44], and thus induce genome-wide hypomethy-
lation, a hallmark of cancer [45].
Inadditiontohigherdietaryintakes,methioninecanalso
be regenerated if more circulating 5-Methyl THF is available
to remethylate homocysteine to methionine, which may be
the case when folate intake is high. However, >700mcg/day
of folate intake through diet and supplements have a weak
inverse association with PC risk, as reported by others [9],
as well as vitamin B6 taken at higher than recommended
levels, though these were not seen in the current study.
Together, our ﬁndings suggest that the driver in the one-
carbon metabolism pathway in diseased PC tissues may be
methionine and not folate and that previous inconsistent
ﬁndings in relation to folate intake or in circulation and
higher PC risk could be attributed to cohorts in which
methioninemetabolismisimpaired[5,46],thoughofcourse
this is purely speculative and future larger studies are needed
to conﬁrm our ﬁndings.
Associations between PC and MTHFR polymorphisms
have been mixed [7, 47–51]. We found no evidence for
an association between MTHFR gene variants and PC risk,
consistent with ﬁndings from others [52]. Carriers heterozy-
gous for C677T have a 35% reduction of MTHFR activity
while homozygous C677C carriers have 70% less MTHFR
enzymatic activity [53]. A1298C variants also reduce enzyme
activity but to a lesser extent [54]. The C677T variant lies in
the catalytic domain at the NH2-terminal region of the pro-
tein, while the A1298C variant lies on the regulatory domain
of the MTHFR enzyme, at the COOH-terminal region of the
protein, where S-adenosyl-methionine binds, allosterically
inhibiting MTHFR [55]. In our study, higher intakes of
methionine reported by PC cases may further diminish
MTHFR function, which would diminish availability of 5-
methyl THF to remethylate homocysteine into methionine,
which in turn may cause homocysteine accumulation, an
eﬀect that has been associated with adenocarcinomas of the
breast and ovary [56, 57].
AssociationsbetweenPCriskandhigherintakesoffolate,
vitamin B6, and vitamin B12 were not evident. Although
we cannot rule out the possibility that our null associations
could have been due to a limited sample size, conﬁrming
these ﬁndings in a larger study will be important. Ulrich
et al. [58] observed an increased colorectal adenoma risk
in individuals with lower intakes of folate and B-vitamins,
particularly in elder populations (over 60yr old), suggesting
that age may modify the association between folate and
cancer risk. Our ﬁndings showed that higher intakes of
vitamin B12, a cofactor in the reaction of methionine
synthase to regenerate methionine from homocysteine [59],
was unrelated to PC risk in contrast to a prior study, which
showed increased overall PC risk [8]. Together, our results
could indicate that methionine metabolism may be impaired
in older men who develop PC, and that consuming higher
intakes of methionine may aggravate this impairment. This
eﬀect could be even more pronounced in individuals carry-
ing the MTHFR A1298C genetic variant. Future research is
needed to understand the underlying mechanism for these
associations, while more studies are needed to determine
whether the eﬀect of high dietary methionine would cause
methylation alterations [44].
The main limitation of this study is the small sample size
and consequent inability to adequately evaluate the role of
common variants in the MTHFR, which limited our ability
for stratiﬁed analyses by PC grade. Also, the small sample
size leads to concerns about type I errors for our signiﬁcant
ﬁndings and type II errors for our null observations. InJournal of Cancer Epidemiology 7
this study, African Americans were at higher risk for PC in
general, though race/ethnic-speciﬁc analyses would beneﬁt
bylargersamplesize.Anotherlimitationisthatdietaryintake
does not account for metabolized nutrients, and circulating
levels of nutrients involved in the one-carbon metabolism
pathway were not measured and neither were the upstream
markers for homocysteine levels. Also, results should be
interpreted and framed as “among screeners” since all cases
and controls have had a PSA test in the past 12 months; thus
it would be uncertain how these ﬁndings would relate to
populations with lower frequency of PSA testing, since diet
quality (and one-carbon nutrient intake) may be related to
screening behaviors. However, this study provides early data
in support of the provocative hypothesis that excessive intake
of one carbon cycle nutrients [29, 30] may be associated with
increased PC risk. We provide novel evidence for increased
PC risk in relation to high intake of methionine as a function
of MTHFR A12986C genotype.
5. Conclusion
In summary, our results suggest that higher intakes of
methionine, presumably through higher protein consump-
tion, is associated with increased PC risk, regardless of
grade of lesion, but only in men carrying the polymorphism
MTHFR A1298C. These ﬁndings remain preliminary and
hypothesis generating. Larger studies are required to validate
these ﬁndings.
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